Oligometastatic Disease Clinical Trial
Official title:
Stereotactic Radiation Therapy for HE2-positive Oligometastatic Breast Cancer
This study involves two non-randomized groups of patients: the observation group and the comparison group. The comparison group will retrospectively include data on 29 patients with oligometastatic HER2-positive breast cancer who received treatment with trastuzumab-emtansine and had a history of SRT. The prospective part of this study aims to include 29 patients with oligometastatic HER2-positive breast cancer. These patients will undergo SRT followed by the administration of trastuzumab emtansine 24 hours after the SRT. The combined effect of stereotactic radiation therapy on a metastatic lesion followed by anti-HER2 therapy in the 2nd line - trastuzumab emtansine, remains unexplored. This study plans to evaluate the effectiveness of combining systemic therapy and local control methods (SRT) in patients with oligometastatic HER2-positive breast cancer. It will be the first time the efficacy and toxic profile of this new combined treatment method in this patient population will be studied. This basket trial evaluates trastuzumab emtansine for oligo-metastatic breast cancer with the aim of inducing deep responses, long-lasting disease remissions, and potentially cure.
This study involves two non-randomized groups of patients: the observation group and the comparison group. The comparison group will retrospectively include data on 29 patients with oligometastatic HER2-positive breast cancer who were treated with trastuzumab-emtansine and had a history of SRT. The dynamics of the process will be evaluated retrospectively using CT and MRI data according to RECIST 1.1 criteria. The main statistical indicators will be calculated based on the patients' medical documentation. The prospective part of this study aims to include 29 patients with oligometastatic HER2-positive breast cancer. These patients will undergo SRT for up to 2 cycles, depending on the location of the irradiated focus, followed by administration of trastuzumab emtansine 3.6 mcg/kg once every 3 weeks, up to 4 total cycles. Trastuzumab emtansine therapy will be initiated 24 hours after the end of the course of SRT. Tumor foci will be assessed according to RECIST 1.1 criteria. Objective response, general condition, and adverse events will be evaluated before, during, and after treatment. Patients will be stratified by age, location of metastatic foci, and treatment. Outpatient patient records, medical histories, clinical and laboratory examination data, morphological examination data, CT findings, MRI findings will be used as sources of information for analyzing the results of diagnosis and treatment. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06190782 -
Local Therapy for Oligometastatic ESCC Patients Treated With PD-1 Inhibitor
|
Phase 3 | |
Not yet recruiting |
NCT06373497 -
Real-Time Atherosclerosis Activity After Thoracic Radiotherapy Using Sodium Fluoride Positron Emission Tomography
|
Early Phase 1 | |
Recruiting |
NCT05377047 -
Stereotactic Ablative Radiotherapy for OligoMetastatic Breast Cancer
|
N/A | |
Recruiting |
NCT05223803 -
TERPS Trial for de Novo Oligometastic Prostate Cancer
|
Phase 2 | |
Recruiting |
NCT04617457 -
Chemotherapy and Surgical Resection in Patients With Hepatic Oligometastatic Adenocarcinoma of the Pancreas
|
Phase 2 | |
Recruiting |
NCT04821765 -
Study of PD-1 Antibody Combined With Chemoradiotherapy in Oligometastatic Esophageal Cancer
|
Phase 2 | |
Recruiting |
NCT05679427 -
Ablative Radiosurgery vs Stereotactic RT in 5 Fractions With SIB for Oligometastatic Bone Lesions
|
N/A | |
Recruiting |
NCT05277844 -
Local Consolidative Radiation Therapy Plus TKI Versus TKI Alone in Driver Mutated OM-NSCLC
|
Phase 2 | |
Active, not recruiting |
NCT05951127 -
Additional Consolidative Esophagectomy for the Patients With Oligometastatic Resectable ESCC
|
N/A | |
Active, not recruiting |
NCT05101824 -
Bony M - Stereotactic Ablative Radiotherapy (SABR) of Bony Metastases in Patients With Oligometastatic Disease
|
N/A | |
Not yet recruiting |
NCT06430411 -
Outcomes of Local Treatment for Oligometastatic Prostate Cancer Diagnosed Using PSMA PET Imaging: OLIGOMET Study
|
||
Recruiting |
NCT04748042 -
Focal Radiation With Pulsed Systemic Therapy of Abiraterone, Androgen Deprivation Therapy (ADT), Lynparza Towards Castration Sensitive Oligometastatic Prostate Cancer (FAALCON)
|
Phase 2 | |
Recruiting |
NCT06122480 -
Surgical Resection of Synchronous Pulmonary or Hepatic Oligometastatic Pancreatic Ductal Adenocarcinoma
|
N/A | |
Not yet recruiting |
NCT05784428 -
Single vs. Multiple Fraction Trial of Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastases/Progression
|
N/A | |
Completed |
NCT04593381 -
Efficacy and Safety of SBRT in Oligo-metastatic/Persistent/Recurrent Ovarian Cancer
|
N/A | |
Terminated |
NCT01345539 -
Radiosurgery for Patients With Oligometastatic Disease at Initial Presentation
|
Phase 2 | |
Recruiting |
NCT05846646 -
Study of PULSAR-ICI +/- IMSA101 in Patients With Oligometastatic NSCLC and RCC
|
Phase 2 | |
Recruiting |
NCT04973007 -
Comparison of Contrast Agents in Liver MR for the Detection of Hepatic Metastases
|
Phase 4 | |
Recruiting |
NCT06439888 -
Lymphocyte Support to SBRT in Patients With Oligo-metastatic Solid Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT05917431 -
Phase 2 Study of SBRT Plus Tislelizumab and Regorafenib in Unresectable or Oligometastatic HCC
|
Phase 2 |